Targeting MicroRNA Blocks Drug Tolerance in Some Cancers

MiRNAs resemble siRNAs of the RNA interference (RNAi) pathway, except miRNAs derive from regions of RNA transcripts that fold back on themselves to form short hairpins, whereas siRNAs derive from longer regions of double-stranded RNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation.

Non-small cell lung cancers, which comprise about 85% of lung cancer diagnoses, tend to be less aggressive but harder to treat than small cell lung cancers. About 10% of non-small-cell lung carcinomas carry an epidermal growth factor receptor (EGFR) mutation. Drug tolerance developed by cancer cells is an acute defense response preceding a fully drug-resistant state and tumor relapse; however, there are few therapeutic agents targeting drug tolerance in the clinic.

As part of their effort to identify drugs able to modify drug tolerance, investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) found that the microRNA miR-147b initiated a reversible state of tolerance to the epidermal growth factor receptor (EGFR) inhibitor osimertinib in non-small-cell lung cancer. Osimertinib is a medication used to treat non-small-cell lung carcinomas with the specific EGFR mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

The investigators reported in the April 8, 2019, online edition of the journal Nature Metabolism that using miRNA-seq analysis, they determined that miR-147b was the most upregulated microRNA in osimertinib-tolerant and EGFR-mutated lung cancer cells. Whole-transcriptome analysis of single-cell-derived clones revealed a link between osimertinib tolerance and pseudohypoxia responses irrespective of oxygen levels.

Further metabolomics and genetic studies demonstrated that osimertinib tolerance was driven by miR-147b-mediated repression of VHL (von Hippel-Lindau tumor suppressor) and succinate dehydrogenase, which are linked to the tricarboxylic acid energy-producing cycle and pseudohypoxia pathways. Finally, pretreatment with a miR-147b inhibitor delayed osimertinib-associated drug tolerance in patient-derived three-dimensional structures.

"These results were a surprise and represent a total novel finding in the area," said senior author Dr. Frank J. Slack, professor of medical research at Beth Israel Deaconess Medical Center. "In this study, we discovered that a microRNA known as miR-147b is a critical mediator of resistance among a subpopulation of tumor cells that adopt a tolerance strategy to defend against EGFR-based anticancer treatments. We are currently testing the idea of targeting this new pathway as a therapy in clinically relevant mouse models of EGFR-mutant lung cancer."

Related Links:
Beth Israel Deaconess Medical Center